Radionuclide therapy; It is used in differentiated thyroid cancer, castration-resistant prostate cancer, neuroendocrine tumors, metastatic and primary liver cancers, bone metastases of many tumors, metastatic pheochromocytoma and neuroblastomas. Delivers radiation to tumorous lesions as part of a treatment strategy to cure, alleviate, or control disease. It can also be used on selected targets or the whole body.
Radioiodine therapy: It is applied in thyroid cancers and toxic (toxic) goiter (Basedow-Graves disease). It is applied to destroy the entire thyroid tissue after surgery in thyroid cancers. Thus, the recurrence and spread of the disease are prevented, and the treatment of metastases is possible. Only normal thyroid or thyroid cancer cells in the body have the ability to retain and store iodine. Therefore, radionuclide iodine therapy is a method specific to the thyroid tissue and has no systematic side effects. It is used in the relapse of the disease after anti-thyroid drug treatment in toxic (poisonous) ogoiter. Radionuclide iodine (Atomic Therapy) destroys thyroid cells and prevents uncontrolled excessive thyroid hormone production.
Radium 223 treatment: Radium 223 is a treatment method used in hormone-resistant prostate cancer cases with bone metastases. It is applied to treat common bone metastases and to relieve pain. This treatment is carried out in a small number of health centers.
MIBG therapy: It is used in the treatment of neuroendocrine tumors such as pheochromocytoma, paraganglioma, neuroblastoma, medullary thyroid carcinoma, carcinoid tumors. In MIBG treatment, radiation is given directly to the tumor, and the effect on healthy tissues is minimal. One dose cures metastatic tumors anywhere in the body. It is a much safer method than traditional radiation treatments.
Lutetium-177 prostate-specific membranous antigen (Lu-177 PSMA) therapy: It is an effective treatment method that has become widespread in recent years in hormone-resistant, metastatic or recurrent prostate cancers. The aim of this treatment is to destroy the tumor and its metastases, reduce its size, and stop the progression of the disease. This "intelligent molecule" developed for a target adheres to tumor cells and creates high radiation damage, while damage to normal tissue cells is extremely low. The application is done in 3-4 periods.
Lutetium-177 peptide receptor radionuclide therapy (PRRT): It is a targeted, safe and effective treatment method used in non-operated well or moderately differentiated, metastatic neuroendocrine tumors. With this treatment, the disease is brought under control and the patient's life expectancy and quality are increased. Karsinold is a complementary treatment method after surgery used in pancreatic, gastrointestinal, bronchial, neuroendocrine tumors and its results are far superior to other treatment methods. It is the first preferred treatment method in cases where primary surgery cannot be performed.
Yttrium-90 (Y-90) radioembolization therapy: Radioembolization is a treatment procedure in which both embolization and radiation therapy are used together. This treatment is used in liver own tumors or liver metastases of other organ cancers that cannot be surgically and liver y-transplanted. Micron-sized particles coated with the radionuclide Y-90 isotope are introduced into the blood vessels feeding the tumor. Thus, the blood supply and nutrition of cancer cells is cut off, and high-dose radiation is given to the tumor. It is a palliative treatment method. The growth of cancer cells in the liver is slowed down, the signs (symptoms) are reduced and delayed.